Hypersensitivity reactions to docetaxel: Retrospective evaluation and development of a desensitization protocol

International Archives of Allergy and Immunology

Volumn 156, Issue 3, 2011, Pages 320-324

  Syrigou, Ekaterini ^a   Dannos, Ioannis ^a   Kotteas, Elias ^a   Makrilia, Nektaria ^a   Tourkantonis, Ioannis ^a   Dilana, Kalliopi ^a   Gkiozos, Ioannis ^a   Saif, Muhammad Wasif ^b   Syrigos, Kostas N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Howard Hughes Medical Institute   (United States)

Author keywords

Desensitization; Docetaxel; Hypersensitivity reactions; Lung cancer

Indexed keywords

BETA LACTAM ANTIBIOTIC; CETIRIZINE; DOCETAXEL; HOUSE DUST ALLERGEN; METHYLPREDNISOLONE; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALTERNARIA ALTERNATA; ARTICLE; ASPERGILLUS FUMIGATUS; BACKACHE; BLOOD PRESSURE MONITORING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION; DILUTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; FLUSHING; HEART RATE; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OXYGEN SATURATION; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SIDE EFFECT; SWELLING; TACHYCARDIA; THORAX PAIN; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 79959680809     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000324454     Document Type: Article

References (37)

1. Shepherd GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24: 253-262. (Pubitemid 36584220)
2. Gruchalla RS: 10. Drug allergy. J Allergy Clin Immunol 2003; 111:S548-S559. (Pubitemid 36223293)
3. Syrigou E, Syrigos K, Saif MW: Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008; 8: 56-62. (Pubitemid 351459694)
4. Castells M: Drug desensitization in oncology: Chemotherapy agents and monoclonal antibodies; in Pichler WJ (ed): Drug Hypersensitivity. Basel, Karger, 2007, pp 413-425.
5. Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK: Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11: 885-890. (Pubitemid 23146083)
6. Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D: Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced nonsmall cell lung cancer: A randomized, multicenter phase III trial. Lung Cancer 2008; 59: 57-63.
7. Syrigos KN, Konstantinou M, Sepsas E, Papamichales G, Loullias A, Belenis I, Skottis I, Charpidou A, Roussos C: Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: A phase II study. Anticancer Res 2007; 27: 2887-2892. (Pubitemid 47228016)
8. Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D: FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: A randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 2010; 119: 95-104.
9. Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V: Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2010; 21: 48-54.
10. Kehoe S, Morrison J: Ovarian cancer (advanced). Clin Evid (Online) 2009;pii:0816.
11. Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K: Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: A single institution study. Am J Clin Oncol 2010; 34: 38-42.
12. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K: Docetaxel plus gemcitabine as firstline treatment in malignant pleural mesothelioma: A single institution phase II study. Anticancer Res 2009; 29: 3441-3444.
13. Polyzos A, Syrigos K, Stergiou J, Panopoulos C, Potamianou A, Vamvakas L, Georgoulias V: Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Cancer Chemother Pharmacol 2005; 55: 466-470. (Pubitemid 40568977)
14. Syrigos KN, Michalaki B, Alevyzaki F, Machairas A, Mandrekas D, Kindilidis K, Karatzas G: A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 2002; 22: 3583-3588. (Pubitemid 36132833)
15. Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, Kentepozidis N, Milaki G, Tzanakis N, Kouroussis C, Vamvakas L, Georgoulias V: A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 2004; 43: 329-333. (Pubitemid 38224154)
16. Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW: Pneumonitis related to docetaxel: Case report and review of the literature. In Vivo 2009; 23: 635-637.
17. Baker J, Ajani J, Scotte F, Winther D, Martin M, Aapro MS, von MG: Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009; 13: 49-59.
18. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D: Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2005; 23: 2937-2945. (Pubitemid 46224112)
19. Markman M: Managing taxane toxicities. Support Care Cancer 2003; 11: 144-147. (Pubitemid 36733807)
20. Syrigos KN, Dannos I, Dionellis G, Bofos I, Alamara C, Dimakou E, Stratakos G, Papiris S: Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for nonsmall cell lung cancer: A phase II study. Anticancer Res 2005; 25: 3489-3493. (Pubitemid 41105228)
21. Karapanagiotou EM, Charpidou A, Tzannou I, Dilana K, Kotteas E, Tourkantonis I, Kosmas E, Provata A, Syrigos K: A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as firstline therapy for non-small cell lung cancer. Med Oncol 2008; 25: 303-308.
22. Syrigos KN, Karapanagiotou E, Charpidou A, Dilana K, Dannos I, Dionellis G, Rigopoulou A, Georgatou N, Roussos C: Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: A phase II study. J Chemother 2007; 19: 438-443. (Pubitemid 47236524)
23. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK: Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82: 550-558. (Pubitemid 32826458)
24. National Cancer Institute: Common Terminology Criteria for Adverse Events. Version 3.0. Index. http://ctep.cancer.gov/protocol Development/ electronic-applications/docs/ ctcae-index.pdf. 2006.
25. Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN: Hypersensitivity reactions to antineoplastic agents: An overview. Anticancer Drugs 2009; 20: 1-6.
26. Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, Syrigos K: Administration of cisplatin in three patients with carboplatin hypersensitivity: Is skin testing useful? Anticancer Drugs 2010; 21: 333-338.
27. Bursztejn AC, Trechot P, Cuny JF, Schmutz JL, Barbaud A: Cutaneous adverse drug reactions during chemotherapy: Consider nonantineoplastic drugs. Contact Dermatitis 2008; 58: 365-368. (Pubitemid 351733057)
28. Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN: Hypersensitivity reactions to oxaliplatin: A retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 2009; 8: 106-109.
29. Von Hoff DD: The taxoids: Same roots, different drugs. Semin Oncol 1997; 24:S13.
30. Denman JP, Gilbar PJ, Abdi EA: Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. J Clin Oncol 2002; 20: 2760-2761. (Pubitemid 34575656)
31. Szebeni J, Muggia FM, Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J Natl Cancer Inst 1998; 90: 300-306. (Pubitemid 28182386)
32. Lenz HJ: Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601-609.
33. Zanotti KM, Markman M: Prevention and management of antineoplastic- induced hypersensitivity reactions. Drug Saf 2001; 24: 767-779. (Pubitemid 32848355)
34. Chouhan JD, Herrington JD: Single premedication dose of dexamethasone 20 mg IV before docetaxel administration. J Oncol Pharm Pract 2010, Epub ahead of print.
35. Zhou JN, Huang XE, Ye Z, Li C, Zhang Q, Lin Y, Jiang W, Sunh WL, Shi MQ, Shu YQ: Weekly paclitaxel/docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: A study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev 2009; 10: 1147-1150.
36. Feldweg AM, Lee CW, Matulonis UA, Castells M: Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: A new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96: 824-829. (Pubitemid 40255508)
37. Lee C, Gianos M, Klaustermeyer WB: Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102: 179-187.